|
Novartis to restructure US business to strengthen competitive position
|
15 January 2012 |
|
Deeper levels of response with Tasigna® compared to Glivec®
|
13 December 2011 |
|
Afinitor® significantly extends time women with advanced breast cancer live without tumor growth
|
08 December 2011 |
|
Novartis Foundation symposium looks at impact of Information and Communication Technology
|
02 December 2011 |
|
Novartis and collaborators discover new dual-acting class of antimalarial compounds
|
17 November 2011 |
|
Novartis appoints Timothy Wright, M.D. as Global Head, Development, Novartis Pharmaceuticals
|
09 November 2011 |
|
Novartis achieves strong third quarter financial performance and pipeline progress
|
26 October 2011 |
|
AIN457 provided rapid and significant relief of symptoms in up to 81% of patients with psoriasis
|
25 October 2011 |
|
Novartis drug Gilenya® (fingolimod) has more than 20,000 patient-years of exposure
|
18 October 2011 |
|
New Novartis data show potential of respiratory portfolio
|
27 September 2011 |